Literature DB >> 30938050

Adalimumab plus topical tacrolimus for the treatment of pyoderma gangrenosum: Report of a case.

Claudio Marasca1, Giuseppina Fontanella1, Maria C Annunziata1, Dario Marasca2, Gabriella Fabbrocini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30938050      PMCID： PMC7949406          DOI： 10.1111/iwj.13123

Source DB:  PubMed          Journal:  Int Wound J        ISSN： 1742-4801            Impact factor:   3.315


× No keyword cloud information.
  10 in total

Review 1.  Pyoderma gangrenosum.

Authors:  N M Blitz; D Rudikoff
Journal:  Mt Sinai J Med       Date:  2001 Sep-Oct

2.  Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab.

Authors:  Michelangelo Vestita; Stefania Guida; Stella Mazzoccoli; Francesco Loconsole; Caterina Foti
Journal:  Eur J Dermatol       Date:  2015 May-Jun       Impact factor: 3.328

Review 3.  Pyoderma gangrenosum: a systematic review.

Authors:  E Cozzani; G Gasparini; A Parodi
Journal:  G Ital Dermatol Venereol       Date:  2014-10       Impact factor: 2.011

4.  A case of axillary hidradenitis suppurativa treated with topical tacrolimus.

Authors:  Claudio Marasca; Maria C Annunziata; Anna Masarà; Gabriella Fabbrocini
Journal:  G Ital Dermatol Venereol       Date:  2018-01-24       Impact factor: 2.011

5.  Pyoderma gangrenosum successfully treated with topical tacrolimus.

Authors:  Maddalena Napolitano; Matteo Megna; Angela Patrì; Giuseppe Monfrecola; Nicola Balato
Journal:  G Ital Dermatol Venereol       Date:  2018-01-24       Impact factor: 2.011

6.  Topical application of the tumour necrosis factor-alpha antibody infliximab improves healing of chronic wounds.

Authors:  Markus Streit; Zsuzsanna Beleznay; Lasse R Braathen
Journal:  Int Wound J       Date:  2006-09       Impact factor: 3.315

7.  Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients.

Authors:  Adam Weizman; Brian Huang; Dror Berel; Stephan R Targan; Marla Dubinsky; Phillip Fleshner; Andrew Ippoliti; Manreet Kaur; Deepa Panikkath; Steve Brant; Ioannis Oikonomou; Rick Duerr; John Rioux; Mark Silverberg; Jerome I Rotter; Eric Vasiliauskas; Talin Haritunians; David Shih; Dalin Li; Gil Y Melmed; Dermot P B McGovern
Journal:  Inflamm Bowel Dis       Date:  2014-03       Impact factor: 5.325

Review 8.  Etiology and management of pyoderma gangrenosum: a comprehensive review.

Authors:  Iris Ahronowitz; Joanna Harp; Kanade Shinkai
Journal:  Am J Clin Dermatol       Date:  2012-06-01       Impact factor: 7.403

9.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

10.  Superficial pyoderma gangrenosum treated with infliximab: a case report.

Authors:  Hamza Bhatti; Nauman Khalid; Babar Rao
Journal:  Cutis       Date:  2012-12
  10 in total
  2 in total

1.  Wound care, adalimumab, and multidisciplinary approach in a patient affected by PASH syndrome.

Authors:  Orlando Zagaria; Angelo Ruggiero; Gabriella Fabbrocini; Lucia Gallo; Marco Romanelli; Claudio Marasca
Journal:  Int Wound J       Date:  2020-05-22       Impact factor: 3.315

2.  Adalimumab in the Management of Isotretinoin-Induced Acne Fulminans: Report of a Case.

Authors:  Claudio Marasca; Gabriella Fabbrocini; Luisa Abategiovanni; Elisa Camela; Mariateresa Nocerino; Adriana Di Guida; Gaia De Fata Salvatores
Journal:  Skin Appendage Disord       Date:  2021-01-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.